marked.bio

neoantigen vaccine · vaccine

MVA-209

2 active trials, targeting frameshift neoantigens. Not approved for any biomarker on marked.bio yet.

Also known as MVA-209-FSP.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
MSI-H / dMMR 2 2 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of MVA-209.

  1. Nouscom 1

Trials

2 of 2 trials shown

  1. Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

    Active, not recruiting Phase 1/2 National Cancer Institute (NCI) Started 2022Primary completion 2025-04 NCT05078866

    Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPMVA-209

    A personal history of a non-sporadic MMR-deficient premalignant lesion (i.e., colorectal polyp) or a non-sporadic MMR-deficient malignant tu…

    MSI-H / dMMRColorectal Carcinoma, Lynch Syndrome

  2. Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

    Active, not recruiting Phase 1/2 Nouscom Started 2019Primary completion 2026-10 NCT04041310

    GAd-209-FSP low doseMVA-209GAd-209-FSP high doseGAd20-209-FSP, RP2Dpembrolizumab FDA EU

    Have previously proven microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status (confirmatory testing is not required)…

    MSI-H / dMMRSolid Tumor, Adult